These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27195949)

  • 1. Antidiabetic medications in patients with heart failure.
    Samia El Hayek MM; Beydoun MF; Azar ST
    Minerva Endocrinol; 2017 Mar; 42(1):53-63. PubMed ID: 27195949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.
    Gilbert RE; Krum H
    Lancet; 2015 May; 385(9982):2107-17. PubMed ID: 26009231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
    Kappel BA; Marx N; Federici M
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):697-705. PubMed ID: 26164634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.
    Fonarow GC
    Am Heart J; 2004 Oct; 148(4):551-8. PubMed ID: 15459582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure?
    Nikolaidis LA; Levine TB
    Cardiol Rev; 2004; 12(3):158-70. PubMed ID: 15078585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials.
    Yang DY; He X; Liang HW; Zhang SZ; Zhong XB; Luo CF; Du ZM; He JG; Zhuang XD; Liao XX
    Cardiovasc Diabetol; 2019 Apr; 18(1):47. PubMed ID: 30961600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin and thiazolidinedione use in Medicare patients with heart failure.
    Masoudi FA; Wang Y; Inzucchi SE; Setaro JF; Havranek EP; Foody JM; Krumholz HM
    JAMA; 2003 Jul; 290(1):81-5. PubMed ID: 12837715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.
    Fisher M
    Diabetes Obes Metab; 2015 Apr; 17(4):335-42. PubMed ID: 25155010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases.
    Lu Q; Li X; Liu J; Sun X; Rousselle T; Ren D; Tong N; Li J
    Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30710062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycemic control and treatment patterns in patients with heart failure.
    Tang WH
    Heart Fail Monit; 2006; 5(1):10-4. PubMed ID: 16547530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications.
    Bell DSH; Goncalves E
    Diabetes Obes Metab; 2019 Jun; 21(6):1277-1290. PubMed ID: 30724013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
    Fisman EZ; Tenenbaum A; Motro M; Adler Y
    Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
    Masoudi FA; Inzucchi SE; Wang Y; Havranek EP; Foody JM; Krumholz HM
    Circulation; 2005 Feb; 111(5):583-90. PubMed ID: 15699279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diabetes mellitus and heart failure: epidemiology and therapy].
    Pfister R; Erdmann E
    Herz; 2008 Apr; 33(3):178-83. PubMed ID: 18568311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EMPA-REG - the "diuretic hypothesis".
    McMurray J
    J Diabetes Complications; 2016; 30(1):3-4. PubMed ID: 26597600
    [No Abstract]   [Full Text] [Related]  

  • 18. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
    Zannad F; Cannon CP; Cushman WC; Bakris GL; Menon V; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Lam H; White WB;
    Lancet; 2015 May; 385(9982):2067-76. PubMed ID: 25765696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Congestive heart failure and diabetes mellitus: an intricated relationship].
    De Flines J; Scheen AJ
    Rev Med Liege; 2007 Feb; 62(2):112-7. PubMed ID: 17461301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
    Tanaka A; Inoue T; Kitakaze M; Oyama J; Sata M; Taguchi I; Shimizu W; Watada H; Tomiyama H; Ako J; Sakata Y; Anzai T; Uematsu M; Suzuki M; Eguchi K; Yamashina A; Saito Y; Sato Y; Ueda S; Murohara T; Node K
    Cardiovasc Diabetol; 2016 Apr; 15():57. PubMed ID: 27044332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.